MULTI-AGENT INFRASTRUCTURES FOR OBJECTIVE AND SUBJECTIVE COORDINATION

Coordination in MAS can be conceived as either an agent activity (the subjective viewpoint) or an activity over agents (the objective viewpoint). The two viewpoints have generated two diverging and often contrasting lines of research, as well as different and non-compatible technologies: however, their integration is mandatory for modelling and engineering complex MAS. In this paper, we explore the issue of integration at both the model and the technology levels. First, by taking FIPA agents and coordination artifacts as reference notions for subjective and objective approaches, respectively, we sketch a framework where agent interactions with coordination artifacts are modelled as physical acts, deliberated and executed by agents analogously to communicative actions. Then, we show how the JADE infrastructure for FIPA-compliant agents, and the TuCSoN infrastructure providing agents with coordination artifacts can be integrated at the technology level, allowing JADE agents to access TuCSoN tuple centres through JADE services

Multi-Agents Corporate Memory Management System

International audienceThis paper presents an approach to design a multi-agent system managing a corporate memory in the form of a distributed semantic web and describes the resulting architecture. The system was designed during the CoMMA European project (Corporate MemoryManagement through Agents) and aims at helping users in the management of a corporate memory, facilitating the creation, dissemination, transmission and reuse of knowledge in an organisation. The implementation integrated several emerging technologies: multi-agents system technology (using the JADE FIPA-compliant platform), knowledge modelling and XML technology for information retrieval (using the CORESE semantic search engine) and machine learning techniques. Here, we describe the agent roles and interactions, we explain the design rationale for the agent societies and we discuss the configuration and implementation issues

Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib

ARQ 197-215 was a randomized placebo-controlled phase II study testing the MET inhibitor tivantinib in second-line hepatocellular carcinoma (HCC) patients. It identified tumor MET as a key biomarker in HCC. Aim of this research was to study the prognostic and predictive value of tumor (MET, the receptor tyrosine kinase encoded by the homonymous MNNG-HOS transforming gene) and circulating (MET, hepatocyte growth factor [HGF], alpha-fetoprotein [AFP], vascular endothelial growth factor [VEGF]) biomarkers in second-line HCC. Tumor MET-High status was centrally assessed by immunohistochemistry. Circulating biomarkers were centrally analyzed on serum samples collected at baseline and every 4-8 weeks, using medians as cut-off to determine High/Low status. Tumor MET, tested in 77 patients, was more frequently High after (82%) versus before (40%) sorafenib. A significant interaction (p = 0.04) between tivantinib and baseline tumor MET in terms of survival was observed. Baseline circulating MET and HGF (102 patients) High status correlated with shorter survival (HR 0.61, p = 0.03, and HR 0.60, p = 0.02, respectively), while the association between AFP (104 patients) or VEGF (103 patients) status and survival was non-significant. Conclusions: Tumor MET levels were higher in patients treated with sorafenib. Circulating biomarkers such as MET and HGF may be prognostic in second-line HCC. These results need to be confirmed in larger randomized clinical trials

CoMMA Corporate Memory Management through Agents Corporate Memory Management through Agents: The CoMMA project final report

This document is the final report of the CoMMA project. It gives an overview of the different search activities that have been achieved through the project. First, a description of the general requirements is proposed through the definition of two scenarios. Then it shows the different technical aspects of the projects and the solution that has been proposed and implemented

Corporate Memory Management through Agents: The CoMMA project final report

This document is the final report of the CoMMA project. It gives an overview of the different search activities that have been achieved through the project. First, a description of the general requirements is proposed through the definition of two scenarios. Then it shows the different technical aspects of the projects and the solution that has been proposed and implemented

Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma

Introduction: Cabozantinib has been approved by the European Medicine Agency (EMA) for hepatocellular carcinoma (HCC) previously treated with sorafenib. Cabozantinib is also being tested in combination with immune checkpoint inhibitors in the frontline setting. Real-life clinical data of cabozantinib for HCC are still lacking. Moreover, the prognostic factors for HCC treated with cabozantinib have not been investigated. Methods: We evaluated clinical data and outcome of HCC patients who received cabozantinib in the legal context of named patient use in Italy. Results: Ninety-six patients from 15 centres received cabozantinib. All patients had preserved liver function (Child-Pugh A), mostly with an advanced HCC (77.1%) in a third-line setting (75.0%). The prevalence of performance status (PS) > 0, macrovascular invasion (MVI), extrahepatic spread, and alpha-fetoprotein (AFP) >400 ng/mL was 50.0, 30.2, 67.7, and 44.8%, respectively. Median overall survival (OS) and progression-free survival were 12.1 (95% confidence interval 9.4–14.8) and 5.1 (3.3–6.9) months, respectively. Most common treatment-related adverse events (AEs) were fatigue (67.7%), diarrhoea (54.2%), anorexia (45.8%), HFSR (43.8%), weight loss (24.0%), and hypertension (24.0%). Most common treatment-related Grade 3–4 AEs were fatigue (6.3%), HFSR (6.3%), and increased aminotransferases (6.3%). MVI, ECOG-PS > 0, and AFP >400 ng/mL predicted a worse OS. Discontinuation for intolerance and no new extrahepatic lesions at the progression were associated with better outcomes. Conclusions: In a real-life Western scenario (mostly in a third-line setting), cabozantinib efficacy and safety data were comparable with those reported in its registration trial. Data regarding the prognostic factors might help in patient selection and design of clinical trials

Assessing the impact of COVID-19 on liver cancer management (CERO-19).

BACKGROUND & AIMS: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated whether the schedule of LC screening or procedures has been interrupted or delayed because of the COVID-19 pandemic. METHODS: An international survey evaluated the impact of the COVID-19 pandemic on clinical practice and clinical trials from March 2020 to June 2020, as the first phase of a multicentre, international, and observational project. The focus was on patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma, cared for around the world during the first COVID-19 pandemic wave. RESULTS: Ninety-one centres expressed interest to participate and 76 were included in the analysis, from Europe, South America, North America, Asia, and Africa (73.7%, 17.1%, 5.3%, 2.6%, and 1.3% per continent, respectively). Eighty-seven percent of the centres modified their clinical practice: 40.8% the diagnostic procedures, 80.9% the screening programme, 50% cancelled curative and/or palliative treatments for LC, and 41.7% modified the liver transplantation programme. Forty-five out of 69 (65.2%) centres in which clinical trials were running modified their treatments in that setting, but 58.1% were able to recruit new patients. The phone call service was modified in 51.4% of centres which had this service before the COVID-19 pandemic (n = 19/37). CONCLUSIONS: The first wave of the COVID-19 pandemic had a tremendous impact on the routine care of patients with liver cancer. Modifications in screening, diagnostic, and treatment algorithms may have significantly impaired the outcome of patients. Ongoing data collection and future analyses will report the benefits and disadvantages of the strategies implemented, aiding future decision-making. LAY SUMMARY: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems globally. Herein, we assessed the impact of the first wave pandemic on patients with liver cancer and found that routine care for these patients has been majorly disrupted, which could have a significant impact on outcomes

On access restriction with Java wildcards

Java wildcards is a new programming mechanism shipped with the Java 5.0 release, introduced to provide a flexible subtyping mechanism for generic types. Safety is retained by providing rather peculiar and non-trivial mechanisms to restrict access to a class functionalities (methods and fields), which are currently not deeply described in the Java Language Specification. In this paper we develop on the theory of variant parametric types from which wildcards originated, and study a framework to describe these access restriction issues in detail, promoting the understanding and fruitful exploitation of this new programming concept. Our work is both technical and conceptual. On the one hand, we provide an abstract characterisation of formal rules to access restriction, then instantiated to the particular implementation of wildcards in current Java. On the other hand, we show that such a characterisation induces a natural description and understanding of access restriction in terms of the ability of (instances of) a generic class to produce/consume elements of the abstracted type